A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Brief description of study

This is an umbrella study designed to learn more about how well different drugs work in non-small cell lung cancer. This study will test MK-4830, MK7-684, and MK-5890 with pembrolizumab and standard chemotherapy or with pembrolizumab alone in subjects with advanced NSCLC.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Carcinoma,Non-Small-Cell Lung
Age: Between 18 Years - 99 Years
Gender: All

Male and female participants diagnosis of squamous or nonsquamous NSCLC

Updated on 09 Mar 2024. Study ID: 843179

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).